• Go to navigation
  • Go to content
AstraZeneca South Africa

You are here

  • Home
  • Therapeutic Areas
  • Gastroenterology

Astrazeneca global websites

  • AstraZeneca Websites

Main navigation

  • Home
  • About us
  • Products
  • Medical Information
  • Managed Healthcare
  • Drug Safety
  • Therapeutic Areas
    • Cardiovascular
    • Gastroenterology
      • References
    • Infection
    • Neuroscience
    • Oncology
    • Pain and Anaesthesia
    • Respiratory
  • Research and Development
  • Corporate Responsibility
  • Community Affairs
  • Price list
  • News
  • Investors
  • Careers
  • Contact us
  • Sitemap

Gastroenterology

 

Many patients who present with persistent, recurring heartburn or other symptoms of gastroesophageal reflux disease (GORD) have tried lifestyle changes, over-the-counter remedies [1] and, possibly, taken prescription therapies that have proven to be unsatisfactory[2]


Definition and description:

GORD is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications [3]. This is the globally accepted Montreal Definition of GORD, which was developed by a Consensus Group of 44 experts from around the world, headed by a core Working Group [3]. They also concluded that the typical GORD syndrome can be diagnosed and managed successfully in primary care without the need for further investigation (if no alarm symptoms present), based on symptoms and their impact on patients’ lives.

Persistent GORD symptoms cause disruption in patients’ lives by interfering with eating, drinking, sleeping and other daily activities [4] , may reduce productivity at work [5] and arouse anxiety about their possible long-term effects [1].

Patients experience varying levels of disruption due to GORD affecting their lives. The Montreal Definition of GORD concluded that reflux symptoms become troublesome when they adversely affect a patient’s well-being.GORD is a potentially serious condition. Repeated oesophageal damage can lead to the development of Barrett’s oesophagus, and a risk of oesophageal adenocarcinoma [6].

Patients with persistent GORD want enduring symptom relief.

By using proton pump inhibitors one can achieve effective acid control[7–9], provide freedom from reflux symptoms[10,11], heal oesophagitis[12,13], maintain freedom from GORD and reduce the disruption and anxiety caused by GORD[14,15]

 Gastroenterology
 References

  • Advanced search

Not signed in



  • Register
  • Forgotten password?

Quick links

  • 010 AZ UK
  • 020 Jobs
  • 030 Key facts
  • 040 Key Products
  • 050 Annual Reports
  • 060 Worldwide Locations
  • 070 PIASA

Page tools

  • Print
  • Bookmark this page

Geography

  • World
  • None
Pharmaceutical Industry Association of South Africa

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2010